Arrowhead pharmaceuticals requests regulatory clearance to initiate phase 1/2a study of aro-mapt for the treatment of alzheimer's disease and other tauopathies

Pasadena, calif.--(business wire)---- $arwr--arrowhead pharmaceuticals, inc. (nasdaq: arwr) today announced that it has filed a request for regulatory clearance to initiate a phase 1/2a clinical trial of aro-mapt, the company's investigational rna interference (rnai) therapeutic being developed as a potential treatment for tauopathies including alzheimer's disease, a progressive neurodegenerative disease characterized by cognitive and functional decline. alzheimer's disease is the most common cause of de.
ARWR Ratings Summary
ARWR Quant Ranking